Companies /Healthcare

Compass Therapeutics Inc

NASDAQ: CMPX Biotechnology
$0.71
▼ $0.06 (−8.10%) today
Markets open · 11:38am ET

CMPX at a Glance

Valuation
Market cap
$139.4M
Profitability
EPS (TTM)
$-0.46
Price
52-week range
$1 – $7
Street target
$5.26

Headquartered in Boston, MA Fiscal year ends December NASDAQ: CMPX compasstherapeutics.com

About Compass Therapeutics

Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage, oncology-focused biopharmaceutical company. It develops proprietary antibody-based therapeutics aimed at the relationship between angiogenesis, the immune system and tumor growth. The company has no product revenue and funds operations from cash and marketable securities.

Its pipeline includes:
- **Tovecimig:** a DLL4 x VEGF-A bispecific antibody. It is in BLA preparation for second-line biliary tract cancer based on the Phase 2/3 COMPANION-002 trial, although the FDA has recommended an additional survival study before submission. It is also being tested in investigator-sponsored trials in first-line BTC, colorectal cancer and glioblastoma.
- **CTX-8371:** a PD-1 x PD-L1 bispecific in Phase 1 expansion cohorts in triple-negative breast cancer, non-small cell lung cancer and Hodgkin lymphoma.
- **CTX-10726:** a tetravalent PD-1 x VEGF-A bispecific in Phase 1 dose escalation in renal cell, gastroesophageal, hepatocellular and endometrial cancers.
- **CTX-471:** a CD137 (4-1BB) agonist antibody entering a Phase 2 study in NCAM-positive Grade 3 neuroendocrine tumors and carcinomas.

The company plans to develop its candidates both as standalone therapies and in combinations within its own pipeline, and is incurring pre-commercialization expenses ahead of a potential tovecimig launch. Updated

CMPX Coverage

Frequently Asked Questions

What does Compass Therapeutics do?

Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage, oncology-focused biopharmaceutical company. It develops proprietary antibody-based therapeutics aimed at the relationship between angiogenesis, the immune system and tumor growth.

What is the CMPX stock price target?

The Wall Street consensus 12-month price target for CMPX is $5.26.